Table 1.
Currently available bypassing agents for treatment and prevention of bleeding
*Based on a 50 kg person receiving 5 mg of rFVIIa or 4000 U of aPCC.
†An 84% reduction in the group of patients with good response and 28% reduction in group of patients with poor response.
